Gregory Sessler is senior vice president, technology development of Olympus Surgical Technologies America (OSTA),a leader in the development of medical devices for many surgical specialties. OSTA is part of Olympus Corporation, based in Tokyo with over 35,000 employees worldwide. Mr. Sessler is responsible for operations of the Redmond Washington site, which is focused on research, development and manufacturing of minimally invasive respiratory devices. Prior to his current role, he was former president, former chief operating officer and former chief financial officer of Spiration, Inc., acquired by Olympus in 2010.
Mr. Sessler’s career includes a series of senior financial officer roles in biotechnology companies including senior vice president and chief financial officer of Rosetta Inpharmatics, Inc., (acquired by Merck & Co), chief financial officer of Sonus Pharmaceuticals, Inc. (now part of Achieve Life Sciences, Inc.), chief financial officer of MicroProbe Corporation (acquired by Becton Dickinson), chief financial officer of Molecular Devices Corp, (now part of Danaher Corp). Mr. Sessler started his career at Price Waterhouse & Co. He received a B.S. in accounting, magna cum laude from Syracuse University and an M.B.A. from the Stanford Graduate School of Business.
Mr. Sessler has served as a member of the board of directors and as chairman of the audit committee of Impinj, Inc. since 2011. He previously served as co-chairman of the board and chairman of the audit committee of Marina Biotech, Inc.; and as a member of board and the audit committee of VLST Corporation, Corixa Corporation (acquired by GlaxoSmithKline plc), Blue Heron Biotechnology, Inc., Icogenex Corporation, and Epoch Biosciences, Inc.Mr. Sessler has been a member of the board of directors of Life Science Washington (previously WBBA) since 2000 including serving on its executive committee and as chair of the board.